Sail For Epilepsy is excited to announce that Jazz Pharmaceuticals has come aboard as a sponsor in 2023. The purpose of this global biopharmaceutical company is to innovate to transform the lives of patients and their families. “In speaking with the team at Jazz, I was struck by how passionate they are about helping people with epilepsy live fuller lives. This mindset matches our goals of inspiration and empowerment. I’m looking forward to working together over the next year,” said Phil Haydon, President of Sail For Epilepsy.  

At Jazz, we’re dedicated to transforming the lives of patients and their families of the epilepsy community and continually work to raise awareness and advocate for those in need. The Sail For Epilepsy program emphasizes this mindset and passion shared by Jazz, and we are proud to come aboard and support its efforts to driving awareness of epilepsy so we can more comprehensively support those who need it.

Ryan Bovia, Head of Epilepsy and Movement Disorders at Jazz Pharmaceuticals.

Jazz’s support of Sail For Epilepsy is evidence of their commitment to the epilepsy community. Through this sponsorship, Sail For Epilepsy will be able to hold a number of education and awareness events along the West Coast of the United States, as well as pursue the Recognizing 26 campaign. This campaign seeks to highlight the statistic that 1 in 26 people will develop epilepsy in their lifetime, by sailing over 2600 nautical miles during 26 separate voyage legs in 2023.

Sail For Epilepsy welcomes all of Jazz as virtual shipmates for this campaign – and on the shared journey to inspire people with epilepsy, their families, and their caregivers to take One More Step to live their lives to the fullest extent possible. 

About Jazz Pharmaceuticals 
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information. 

Leave a Reply

Your email address will not be published. Required fields are marked *

Share via
Copy link
Powered by Social Snap